

10/542577  
JC17 Rec'd PCT/PTO 19 JUL 2005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A hemostatic material comprising as an effective ingredient thrombin and fibrinogen held on a supporting material consisting of ~~characterized in that a bioabsorbable synthetic nonwoven fabric is used as a supporting material.~~

2. (original) The hemostatic material according to claim 1, wherein said bioabsorbable synthetic nonwoven fabric is made of a material selected from the group consisting of polyglycolic acid, polylactic acid and a copolymer of glycolic acid and lactic acid.

3. (currently amended) The hemostatic material according to claim 1-~~or 2~~, wherein said bioabsorbable synthetic nonwoven fabric is a nonwoven fabric made of a material of polyglycolic acid.

4. (currently amended) The hemostatic material according to ~~any of claims 1-to-3~~, wherein the bioabsorbable synthetic nonwoven fabric previously holds at least thrombin among thrombin and fibrinogen.

5. (currently amended) The hemostatic material according to ~~any of claims 1-to-4~~, wherein said hemostatic material comprises at least one additive selected from Factor XIII, a protease inhibitor, or calcium chloride.

6. (currently amended) The hemostatic material according to ~~any of claims 1-to-5~~, wherein thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.

7-13 (cancelled)

14. (currently amended) ~~The use according to claim 13, wherein said A method of preparing a bioabsorbable synthetic nonwoven fabric holding thrombin as an effective ingredient, is prepared by comprising the steps of immersing a bioabsorbable synthetic nonwoven fabric into a solution containing thrombin and of lyophilizing the obtained nonwoven fabric.~~

15. (currently amended) The ~~use~~method according to claim ~~13 or 14~~, wherein said bioabsorbable synthetic nonwoven fabric is made of a material selected from the group consisting of polyglycolic acid, polylactic acid and a copolymer of glycolic acid and lactic acid.

16. (currently amended) The ~~use~~method according to ~~any of claims 143 to 15~~, wherein said bioabsorbable synthetic nonwoven fabric is a nonwoven fabric made of a material of polyglycolic acid.

17. (currently amended) The ~~use~~method according to ~~any of claims 143 to 16~~, wherein said hemostatic material comprises at least one additive selected from Factor XIII, a protease inhibitor, or calcium chloride.

18. (currently amended) The ~~use~~method according to claim 17, wherein said calcium chloride is fixed to the bioabsorbable synthetic nonwoven fabric together with thrombin.

19. (currently amended) The ~~use~~method according to claim 17-~~or~~<sup>18</sup>, wherein said Factor XIII is added to fibrinogen.

20. (currently amended) The ~~use~~method according to ~~any of claims 143 to 19~~, wherein said thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.

21. (original) A hemostatic kit comprising a bioabsorbable synthetic nonwoven fabric holding thrombin as an effective ingredient, and a container comprising fibrinogen as an effective ingredient.

22. (original) The hemostatic kit according to claim 21, wherein said bioabsorbable synthetic nonwoven fabric is made of a material selected from the group consisting of polyglycolic acid, polylactic acid and a copolymer of glycolic acid and lactic acid.

23. (currently amended) The hemostatic kit according to claim 21-~~or~~<sup>22</sup>, wherein said bioabsorbable synthetic nonwoven fabric is a nonwoven fabric made of a material of polyglycolic acid.

24. (currently amended) The hemostatic kit according to ~~any of claims 21-to-23~~, wherein said hemostatic kit comprises at least one additive selected from Factor XIII, a protease inhibitor, or calcium chloride.

25. (original) The hemostatic kit according to claim 24, wherein said calcium chloride is added to the bioabsorbable synthetic nonwoven fabric as an additive for thrombin.

26. (currently amended) The hemostatic kit according to claim 24-~~or 25~~, wherein said Factor XIII is included in a container comprising fibrinogen.

27. (currently amended) The hemostatic kit according to ~~any of claims 21-to-26~~, wherein said thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.

28. (currently amended) The hemostatic kit according to ~~any of claims 21-to-27~~, wherein said bioabsorbable synthetic nonwoven fabric holding thrombin is prepared by the steps of immersing a bioabsorbable synthetic

nonwoven fabric into a solution containing thrombin and of lyophilizing the obtained nonwoven fabric.

29. (original) A hemostatic kit comprising a bioabsorbable synthetic nonwoven fabric as a substrate, a container comprising thrombin as an effective ingredient and a container comprising fibrinogen as an effective ingredient.

30. (original) The hemostatic kit according to claim 29, wherein said bioabsorbable synthetic nonwoven fabric is made of a material selected from the group consisting of polyglycolic acid, polylactic acid and a copolymer of glycolic acid and lactic acid.

31. (currently amended) The hemostatic kit according to claim 29 or 30, wherein said bioabsorbable synthetic nonwoven fabric is a nonwoven fabric made of a material of polyglycolic acid.

32. (currently amended) The hemostatic kit according to any of claims 29 to 31, wherein said hemostatic kit comprises at least one additive selected from Factor XIII, a protease inhibitor, or calcium chloride.

33. (original) The hemostatic kit according to claim 32, wherein said Factor XIII is included in a container comprising fibrinogen.

34. (currently amended) The hemostatic kit according to ~~any of claims 29 to 33~~, wherein said thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.